scholarly journals Designing Drug Regimens that Mitigate Nonadherence

2021 ◽  
Vol 84 (1) ◽  
Author(s):  
Elijah D. Counterman ◽  
Sean D. Lawley
Keyword(s):  
Drug Regimens

Synthesis and Anti-mycobacterium Study on Halo-substituted 2-aryl oxyacetohydrazones

2020 ◽  
Vol 16 (5) ◽  
pp. 618-628 ◽  
Author(s):  
Vijay J. Desale ◽  
Suraj N. Mali ◽  
Hemchandra K. Chaudhari ◽  
Maya C. Mali ◽  
Bapu R. Thorat ◽  
...  
Keyword(s):  
Uv Spectroscopy ◽  
Health Concern ◽  
Multiple Drug ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
H37rv Strain ◽  
Mdr Tb ◽  
Drug Regimens ◽  
Ft Ir ◽  
Mycobacteria Tuberculosis

Background: The treatment of multiple-drug-resistant tuberculosis (MDR-TB) with currently available marketed drugs remains a global health concern. The cases of resistant tuberculosis patients are increasing day by day. Objective: The objective of this study is to highlight the need of developing shorter, simpler and tolerable drug regimens. Methods: In the present study, we synthesized various halo-substituted 2-aryloxyacetohydrazones via a series of reactions from halo-substituted phenols. All the compounds were characterized by using various spectroscopic methods, such as NMR, FT-IR, UV spectroscopy, etc. Results: All the synthesized hydrazones showed theoretically good interactions with enzyme enoyl reductase (pdb id: 4tzk). All the synthesized compounds (5a-5o) showed moderate to good activity (3.125-100 μg/mL) against Mycobacteria tuberculosis, H37RV strain. Conclusion: Our results would pave a new way for the development of more effective Anti-TB agents in the future.

scholarly journals Risk of 30-day hospital readmission associated with medical conditions and drug regimens of polymedicated, older inpatients discharged home: a registry-based cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. e052755
Author(s):  
Filipa Pereira ◽  
Henk Verloo ◽  
Taushanov Zhivko ◽  
Saviana Di Giovanni ◽  
Carla Meyer-Massetti ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hospital Readmission ◽  
Hospital Readmissions ◽  
Drug Regimen ◽  
Hospital Length ◽  
Hospital Length Of Stay ◽  
Day Hospital ◽  
Medical Conditions ◽  
Older Inpatients ◽  
Drug Regimens

ObjectivesThe present study analysed 4 years of a hospital register (2015–2018) to determine the risk of 30-day hospital readmission associated with the medical conditions and drug regimens of polymedicated, older inpatients discharged home.DesignRegistry-based cohort study.SettingValais Hospital—a public general hospital centre in the French-speaking part of Switzerland.ParticipantsWe explored the electronic records of 20 422 inpatient stays by polymedicated, home-dwelling older adults held in the hospital’s patient register. We identified 13 802 hospital readmissions involving 8878 separate patients over 64 years old.Outcome measuresSociodemographic characteristics, medical conditions and drug regimen data associated with risk of readmission within 30 days of discharge.ResultsThe overall 30-day hospital readmission rate was 7.8%. Adjusted multivariate analyses revealed increased risk of hospital readmission for patients with longer hospital length of stay (OR=1.014 per additional day; 95% CI 1.006 to 1.021), impaired mobility (OR=1.218; 95% CI 1.039 to 1.427), multimorbidity (OR=1.419 per additional International Classification of Diseases, 10th Revision condition; 95% CI 1.282 to 1.572), tumorous disease (OR=2.538; 95% CI 2.089 to 3.082), polypharmacy (OR=1.043 per additional drug prescribed; 95% CI 1.028 to 1.058), and certain specific drugs, including antiemetics and antinauseants (OR=3.216 per additional drug unit taken; 95% CI 1.842 to 5.617), antihypertensives (OR=1.771; 95% CI 1.287 to 2.438), drugs for functional gastrointestinal disorders (OR=1.424; 95% CI 1.166 to 1.739), systemic hormonal preparations (OR=1.207; 95% CI 1.052 to 1.385) and vitamins (OR=1.201; 95% CI 1.049 to 1.374), as well as concurrent use of beta-blocking agents and drugs for acid-related disorders (OR=1.367; 95% CI 1.046 to 1.788).ConclusionsThirty-day hospital readmission risk was associated with longer hospital length of stay, health disorders, polypharmacy and drug regimens. The drug regimen patterns increasing the risk of hospital readmission were very heterogeneous. Further research is needed to explore hospital readmissions caused solely by specific drugs and drug–drug interactions.

Virologic Outcomes of Complex Drug Regimens for Human Immunodeficiency Virus—Reply

JAMA ◽  
2002 ◽  
Vol 288 (19) ◽  
pp. 2406
Author(s):  
Scott M. Hammer ◽  
Florin Vaida ◽  
Kara K. Bennett ◽  
John W. Mellors
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immunodeficiency Virus ◽  
Drug Regimens ◽  
Complex Drug

scholarly journals Thiosemicarbazole (Thiacetazone-Like) Compound with Activity against Mycobacterium avium in Mice

2003 ◽  
Vol 47 (8) ◽  
pp. 2685-2687 ◽  
Author(s):  
Luiz E. Bermudez ◽  
Robert Reynolds ◽  
Peter Kolonoski ◽  
Pricilla Aralar ◽  
Clark B. Inderlied ◽  
...  
Keyword(s):  
Mycobacterium Avium ◽  
Significant Activity ◽  
In Vitro Screening ◽  
Single Drug ◽  
Drug Regimens

ABSTRACT In vitro screening of thiacetazone derivatives indicated that two derivatives, SRI-286 and SRI-224, inhibited a panel of 25 Mycobacterium avium complex (MAC) isolates at concentrations of 2 μg/ml or lower. In mice, SRI-224 and thiacetazone had no significant activity against the MAC in livers and spleens, but treatment with SRI-286 resulted in significant reduction of bacterial loads in livers and spleens. A combination of SRI-286 and moxifloxacin was significantly more active than single drug regimens in liver and spleen.

scholarly journals Monkey Models of Tuberculosis: Lessons Learned

2014 ◽  
Vol 83 (3) ◽  
pp. 852-862 ◽  
Author(s):  
Juliet C. Peña ◽  
Wen-Zhe Ho
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Animal Models ◽  
Nonhuman Primates ◽  
Lessons Learned ◽  
Preclinical Testing ◽  
Content Type ◽  
Cynomolgus Macaques ◽  
Drug Regimens

The use of animal models has been invaluable for studying the pathogenesis ofMycobacterium tuberculosisinfection, as well as for testing the efficacy of vaccines and drug regimens for tuberculosis. Among the applied animal models, nonhuman primates, particularly macaques, share the greatest anatomical and physiological similarities with humans. As such, macaque models have been used for investigating tuberculosis pathogenesis and preclinical testing of drugs and vaccines. This review focuses on published major studies which illustrate how the rhesus and cynomolgus macaques have enriched and may continue to advance the field of global tuberculosis research.

Heart Failure Therapy in 2016

2016 ◽  
Vol 51 (1) ◽  
pp. 79-82
Author(s):  
Douglas L. Jennings
Keyword(s):  
Heart Failure ◽  
Recent Literature ◽  
Residual Disease ◽  
Angiotensin Receptor ◽  
Heart Failure Therapy ◽  
Call To Action ◽  
Neprilysin Inhibitor ◽  
Drug Regimens ◽  
Contemporary Practice

Heart failure (HF) continues to afflict millions of Americans, resulting in substantial clinical and economic burden to our society. Recent literature has highlighted the role of 2 novel therapies (an angiotensin receptor blocker/neprilysin inhibitor and ivabradine) in further reducing residual disease in HF. Simultaneously, evidence has mounted suggesting that older therapies like digoxin are not effective in contemporary practice and, in fact, may be harmful. This editorial summarizes the most recently published articles pertaining to both new and old HF therapies and provides a call to action to pharmacists on how to shift patients toward effective drug regimens.

Sign in / Sign up

Export Citation Format

Share Document